Business Context and Reporting Period
OrthoPediatrics Corp. (Nasdaq: KIDS) filed a Form 8-K on June 13, 2022, reporting the entry into a Material Definitive Agreement. The Company, through its newly formed indirect wholly-owned subsidiary OrthoPediatrics Canada ULC, agreed to acquire Pega Medical Inc., a developer of trauma and deformity correction devices for children, including the Fassier-Duval Telescopic Intramedullary System.
Key Financial Metrics and Transaction Details
The total purchase consideration for Pega Medical is approximately CAD $42.3 million (USD $33.1 million), structured as follows:
- Cash Consideration: Approximately CAD $39.7 million (USD $31.1 million), subject to working capital adjustments and transaction expense reductions.
- Stock Consideration: Approximately CAD $1.9 million (USD $1.5 million) in OrthoPediatrics Corp. common stock.
- Restricted Stock Units (RSUs): Approximately CAD $640,000 (USD $501,000) issued to Pega Medical employees with a three-year vesting schedule.
Escrow Arrangements:
- CAD $200,000 (USD $157,000) held for post-closing working capital adjustments.
- Approximately CAD $1.6 million (USD $1.2 million) held for up to 18 months to cover indemnification obligations.
The filing does not provide specific revenue, profit, cash flow, or debt metrics for OrthoPediatrics Corp. or Pega Medical Inc. beyond the transaction values.
Material Changes and Conditions
This filing represents a material change in the Company's business operations through the planned acquisition of a new product portfolio and market presence in Canada. The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2022. The number of common shares to be issued will be determined based on the 15-day volume-weighted average trading price ending five trading days prior to closing.
Outlook, Risks, and Contingencies
Repurchase Rights: The Company retains a repurchase right for the common stock issued to Selling Shareholders if they leave employment with Pega Medical for certain reasons within three years of closing. The repurchase price is set at USD $0.10 per share.
Risk Factors: The filing includes standard disclaimers regarding representations and warranties, noting they may not reflect the actual state of facts at the time of the filing and are subject to confidential disclosure schedules. The transaction is contingent on closing conditions being met.
Investor Verification Checklist
- Verify the final closing date and whether the transaction closes in Q3 2022 as expected.
- Confirm the final number of shares issued based on the 15-day volume-weighted average price at closing.
- Review the final working capital adjustment and any resulting changes to the cash consideration.
- Monitor for any regulatory approvals required for the acquisition in Canada or the U.S.
- Assess the integration plan for the Fassier-Duval Telescopic Intramedullary System into OrthoPediatrics' existing product line.